NAS:VKTX (USA) Also trade in: Germany UK

Viking Therapeutics Inc

$ 8.22 -0.03 (-0.36%)
Volume: 1,002,349 Avg Vol (1m): 1,584,858
Market Cap $: 592.24 Mil Enterprise Value $: 293.53 Mil
P/E (TTM): 0.00 P/B: 1.99
Earnings Power Value 0
Net Current Asset Value 4.09
Tangible Book 4.11
Projected FCF 2
Median P/S Value 0
Graham Number 0
Peter Lynch Value 0
DCF (FCF Based) 0
DCF (Earnings Based) 0
1Y (-%)

Financial Strength : 6.4/10

GuruFocus Financial Strength Rank measures how strong a company's financial situation is . It is based on these factors
1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.
A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.
Current vs industry vs history
Cash-to-Debt No Debt
Cash-To-Debt range over the past 10 years
Min: 0.19, Med: 5.17, Max: 10000
Current: 10000
0.19
10000
Piotroski F-Score 4
0
1
2
3
4
5
6
7
8
9
Altman Z-Score 65.60
DISTRESS
GREY
SAFE
WACC vs ROIC %
ROIC 0%
WACC 21.87%

Profitability & Growth : 3/10

GuruFocus Profitability Rank ranks how profitable a company is and how likely the company's business will stay that way.
Current vs industry vs history
ROE % -10.58
ROE range over the past 10 years
Min: -191.36, Med: -175.72, Max: -10.58
Current: -10.58
-191.36
-10.58
ROA % -10.35
ROA range over the past 10 years
Min: -1357.99, Med: -137.25, Max: -10.35
Current: -10.35
-1357.99
-10.35
3-Year Total EBITDA Growth Rate 1.10
3-Year EBITDA Growth Rate range over the past 10 years
Min: 0, Med: -86.65, Max: 52.6
Current: 52.6
0
52.6
3-Year EPS w/o NRI Growth Rate 53.10
3-Year EPS w/o NRI Growth Rate range over the past 10 years
Min: 0, Med: -73.15, Max: 53.1
Current: 53.1
0
53.1

» VKTX's 30-Y Financials

Financials (Next Earnings Date: 2019-08-09)

Guru Trades Click for details

» Details

Insider Trades

SEC Filings

Gurus Latest Trades with NAS:VKTX

» Interactive Chart

Peter Lynch Chart

Business Description

Industry Biotechnology » Biotechnology    NAICS : 325412    SIC : 2834
Compare NAS:FTSV TSX:RVX NAS:OBSV XKRX:083790 NAS:AXSM NAS:CRNX TSX:ZYME LSE:OXB NAS:RVNC TSE:2931 NAS:KURA XAMS:PHARM NAS:LXRX SHSE:600866 NAS:DERM XKRX:005690 NAS:SRRK SZSE:300653 SHSE:603566 TSX:AUP
Traded in other countries 1VT.Germany 0VQA.UK
Address 12340 El Camino Real, Suite 250, San Diego, CA, USA, 92130
Viking Therapeutics Inc is a healthcare service provider. The company specializes in the area of biopharmaceutical development focused on metabolic and endocrine disorders. The company's clinical program, VK5211, is an orally available drug candidate, which is in Phase II clinical trial for acute rehabilitation following non-elective hip fracture surgery. Its second program is focused on the development of orally available small molecule thyroid hormone receptor beta agonists.

Ratios

Current vs industry vs history
PB Ratio 1.99
PB Ratio range over the past 10 years
Min: 0, Med: 0, Max: 90.88
Current: 1.99
0
90.88
EV-to-EBIT -13.75
EV-to-EBIT range over the past 10 years
Min: -57.78, Med: 0, Max: 0
Current: -13.75
-57.78
0
EV-to-EBITDA -13.75
EV-to-EBITDA range over the past 10 years
Min: -57.78, Med: 0, Max: 0
Current: -13.75
-57.78
0
Current Ratio 60.82
Current Ratio range over the past 10 years
Min: 0.01, Med: 3.19, Max: 66.4
Current: 60.82
0.01
66.4
Quick Ratio 60.82
Quick Ratio range over the past 10 years
Min: 0.01, Med: 3.19, Max: 66.4
Current: 60.82
0.01
66.4

Dividend & Buy Back

Current vs industry vs history
3-Year Share Buyback Rate -81.20
3-Year Share Buyback Rate range over the past 10 years
Min: -81.2, Med: -57.85, Max: 0
Current: -81.2
-81.2
0

Valuation & Return

Current vs industry vs history
Price-to-Tangible-Book 2.00
Price-to-Tangible-Book range over the past 10 years
Min: 1.84, Med: 3.86, Max: 22.5
Current: 2
1.84
22.5
Price-to-Projected-FCF 4.11
Price-to-Intrinsic-Value-Projected-FCF range over the past 10 years
Min: 3.63, Med: 4.3, Max: 4.97
Current: 4.11
3.63
4.97
Earnings Yield (Joel Greenblatt) % -7.22
Earnings Yield (Greenblatt) range over the past 10 years
Min: -1995.01, Med: 0, Max: 0
Current: -7.22
-1995.01
0

More Statistics

Analyst Estimate

Piotroski F-Score Details

Piotroski F-Score 4
Positive ROA N
Positive CFROA N
Higher ROA yoy Y
CFROA > ROA Y
Lower Leverage yoy Y
Higher Current Ratio yoy Y
Less Shares Outstanding yoy N
Higher Gross Margin yoy N
Higher Asset Turnover yoy N